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Abstract
The identification of novel drug-target (DT) interactions is a substantial part of the drug
discovery process. Most of the computational methods that have been proposed to predict
DT interactions have focused on binary classification, where the goal is to determine whether
a DT pair interacts or not. However, protein-ligand interactions assume a continuum of
binding strength values, also called binding affinity and predicting this value still remains a
challenge. The increase in the affinity data available in DT knowledge-bases allows the use of
advanced learning techniques such as deep learning architectures in the prediction of binding
affinities. In this study, we propose a deep-learning based model that uses only sequence
information of both targets and drugs to predict DT interaction binding affinities. The few
studies that focus on DT binding affinity prediction use either 3D structures of protein-
ligand complexes or 2D features of compounds. One novel approach used in this work is the
modeling of protein sequences and compound 1D representations with convolutional neural
networks (CNNs). The results show that the proposed deep learning based model that uses
the 1D representations of targets and drugs is an effective approach for drug target binding
affinity prediction. The model in which high-level representations of a drug and a target
are constructed via CNNs achieved the best Concordance Index (CI) performance in one
of our larger benchmark data sets, outperforming the KronRLS algorithm and SimBoost, a
state-of-the-art method for DT binding affinity prediction.
Introduction
The successful identification of drug-target interactions (DTI) is a critical step in drug dis-
covery. As the field of drug discovery expands with the discovery of new drugs, repurposing
of existing drugs and identification of novel interacting partners for approved drugs is also
gaining interest [44]. Until recently, DTI prediction was approached as a binary classifica-
tion problem [4, 6, 7, 15, 25, 45, 56, 61], neglecting an important piece of information about
protein-ligand interactions, namely the binding affinity values. Binding affinity provides
2information on the strength of the interaction between a drug-target (DT) pair and it is
usually expressed in measures such as dissociation constant (Kd), inhibition constant (Ki),
or the half maximal inhibitory concentration (IC50). IC50 depends on the concentration
of the target and ligand [8] and low IC50 values signal strong binding. Similarly, low Ki
values indicate high binding affinity. Kd and Ki values are usually represented in terms of
pKd or pKi, the negative logarithm of the dissociation or inhibition constants.
In binary classification based DTI prediction studies, construction of the data sets con-
stitutes a major problem, since negative (not-binding) information is generally hard to find.
In most cases, the DT pairs for which binding information is not known are treated as nega-
tive (not-binding) samples. The lack of true-negative samples and how the study generates
synthetic negative samples usually affects the performance of the prediction algorithms. On
the other hand, formulating the DT prediction task as a binding affinity prediction problem
enables the creation of more realistic data sets, where the binding affinity scores are directly
used, obviating the need for the generation of synthetic negative samples.
Prediction of protein-ligand binding affinities has been the focus of protein-ligand scoring,
which is frequently used after virtual screening and docking campaigns in order to predict
the putative strengths of the proposed ligands to the target [48]. Non-parametric machine
learning methods such as the Random Forest (RF) algorithm have been used as a successful
alternative to scoring functions that depend on multiple parameters [3, 38, 50]. However,
Gabel et al. showed that RF-score failed in virtual screening and docking tests, speculating
that using features such as co-occurrence of atom-pairs over-simplified the description of the
protein-ligand complex and led to the loss of information that the raw interaction complex
could provide [22]. Around the same time this study was published, deep learning started to
become a popular architecture powered by the increase in data and high capacity computing
machines challenging machine learning methods.
Inspired by the remarkable success rate in image processing [14,18,51] and speech recog-
nition [16, 27, 30], deep learning methods are now being intensively used in many other
research fields, including bioinformatics such as in genomics studies [37,60] and quantitative-
structure activity relationship (QSAR) studies in drug discovery [40]. The major advantage
of deep learning architectures is that they enable better representations of the raw data by
non-linear transformations in each layer [36] and thus they facilitate learning the hidden
patterns in the data.
A few studies employing Deep Neural Networks (DNN) have already been performed for
DTI binary class prediction using different input models for proteins and drugs [9,28,55] in
addition to some studies that employ stacked auto-encoders [58] and deep-belief networks
[59]. Similarly, stacked auto-encoder based models with Recurrent Neural Networks (RNNs)
and Convolutional Neural Networks (CNNs) were applied to represent chemical and genomic
structures in real-valued vector forms [24, 32]. Deep learning approaches have also been
applied to protein-ligand interaction scoring in which a common application has been the
use of CNNs that learn from the 3D structures of the protein-ligand complexes [23, 48, 57].
However, this approach is limited to known protein-ligand complex structures, with only
25000 ligands reported in PDB [49].
Pahikkala et al. employed the Kronecker Regularized Least Squares (KronRLS) algo-
rithm that utilizes only 2D based compound similarity-based representations of the drugs
and Smith-Waterman similarity representation of the targets [47]. Recently, SimBoost
method was proposed to predict binding affinity scores with a gradient boosting machine by
3using feature engineering to represent drug-target interactions [29]. They utilized similarity-
based information of DT pairs as well as features that were extracted from network-based
interactions between the pairs. Both studies used traditional machine learning algorithms
and utilized 2D-representations of the compounds in order to obtain similarity information.
In this study, we propose an approach to predict the binding affinities of protein-ligand
interactions with deep learning models using only sequences (1D representations) of proteins
and ligands. To this end, the sequences of the proteins and SMILES (Simplified Molecular
Input Line Entry System) representations of the compounds are used rather than exter-
nal features or 3D-structures of the binding complexes. We employ CNN blocks to learn
representations from the raw protein sequences and SMILES strings and combine these
representations to feed into a fully-connected layer block that we call DeepDTA. We use
the Davis Kinase binding affinity data set [17] and the KIBA large-scale kinase inhibitors
bioactivity data [29,54] to evaluate the performance of our model and compare our results
with the KronRLS [47] and SimBoost algorithms [29]. Our new model that uses two sepa-
rate CNN-based blocks to represent proteins and drugs performs as well as the KronRLS
and SimBoost algorithms on the Davis data set, and it performs significantly better than
both the KronRLS and SimBoost algorithms on the KIBA data (p-value, 0.0001). With
our proposed model, we also obtain the lowest Mean Squared Error (MSE) value on both
data sets.
Materials and Methods
Data sets
We evaluated our proposed model on two different data sets, the Kinase data set Davis [17]
and KIBA data set [54], which were previously used as benchmark data sets for binding
affinity prediction evaluation [29,47].
The Davis data set contains selectivity assays of the kinase protein family and the relevant
inhibitors with their respective dissociation constant (Kd) values. It comprises interactions
of 442 proteins and 68 ligands. The KIBA data set, on the other hand, originated from an
approach called KIBA, in which kinase inhibitor bioactivities from different sources such
as Ki, Kd, and IC50 were combined [54]. KIBA scores were constructed to optimize the
consistency between Ki, Kd, and IC50 by utilizing the statistical information they contained.
The KIBA data set originally comprised 467 targets and 52498 drugs. [29] filtered it to
contain only drugs and targets with at least 10 interactions yielding a total of 229 unique
proteins and 2111 unique drugs. Table 1 summarizes these data sets in the forms that we
used in our experiments.
Table 1. Data set
Proteins Compounds Interactions
Davis (Kd) 442 68 30056
KIBA 229 2111 118254
While [47] used the Kd values of the Davis data set directly as the binding affinity values,
we used the values transformed into log space, pKd, similar to [29] as explained in Equation
41.
pKd = −log10(
Kd
1e9
) (1)
Figure 1A (left panel) illustrates the distribution of the binding affinity values in pKd form.
The peak at pKd value 5 (10000nM) constitutes more than half of the data set (20931 out
of 30056). These values correspond to the negative pairs that either have very weak binding
affinities (Kd > 10000nM) or are not observed in the primary screen [47]. As such they are
true negatives.
The distribution of the KIBA scores is depicted in the right panel of Figure 1A. [29]
pre-processed the KIBA scores as follows: (i) for each KIBA score, its negative was taken,
(ii) the minimum value among the negatives was chosen, and (iii) the absolute value of the
minimum was added to all negative scores, thus constructing the final form of the KIBA
scores.
The compound SMILES strings of the Davis data set were extracted from the Pubchem
compound database based on their Pubchem CIDs [5]. For KIBA, first the CHEMBL IDs
were converted into Pubchem CIDs and then, the corresponding CIDs were used to extract
the SMILES strings. Figure 1B illustrates the distribution of the lengths of the SMILES
strings of the compounds in the Davis (left) and KIBA (right) data sets. For the compounds
of the Davis dataset, the maximum length of a SMILES is 103, while the average length is
equal to 64. For the compounds of KIBA, the maximum length of a SMILES is 590, while
the average length is equal to 58.
The protein sequences of the Davis data set were extracted from the UniProt protein
database based on gene names/RefSeq accession numbers [2]. Similarly, the UniProt IDs
of the targets in the KIBA data set were used to collect the protein sequences. Figure 1C
left panel shows the lengths of the sequences of the proteins in the Davis data set. The
maximum length of a protein sequence is 2549 and the average length is 788 characters.
Figure 1C right panel depicts the distribution of protein sequence length in KIBA targets.
The maximum length of a protein sequence is 4128 and the average length is 728 characters.
We should also note that the Smith-Waterman (S-W) similarity among proteins of the
KIBA data set is at most 60% for 99% of the protein pairs. The target similarity is at most
60% for 92% of the protein pairs for the Davis data set. These statistics indicate that both
data sets are non-redundant.
Input Representation
We used integer/label encoding that uses integers for the categories to represent inputs. We
scanned approximately 2M SMILES sequences that we collected from Pubchem and com-
piled 64 labels (unique letters). For protein sequences, we scanned 550K protein sequences
from UniProt and extracted 25 categories (unique letters).
Here we represent each label with a corresponding integer (e.g. “C”:1, “H”:2, ‘N”:3 etc.).
The label encoding for the example SMILES, “CN=C=O”, is given below.
[
C N = C = O
]
=
[
1 3 63 1 63 5
]
Protein sequences are encoded in a similar way using label encodings. Both SMILES and
protein sequences have varying lengths. Hence, in order to create an effective representation
5Figure 1. Summary of the Davis (left panel) and KIBA (right panel) data sets. A)
Distribution of binding affinity values B) Distribution of the lengths of the SMILES strings
C) Distribution of the lengths of the protein sequences .
6form, we decided on fixed maximum lengths of 85 for SMILES and 1200 for protein sequences
for Davis. To represent the components of KIBA, we chose the maximum 100 characters
length for SMILES and 1000 for protein sequences. We chose these maximum lengths based
on the distributions illustrated in Figure 1B and 1C so that the maximum lengths cover
at least 80% of the proteins and 90% of the compounds in the data sets. The sequences
that are longer than the maximum length are truncated, whereas shorter sequences are
0-padded.
Proposed Model
In this study we treated protein-ligand interaction prediction as a regression problem by
aiming to predict the binding affinity scores. As a prediction model, we adopted a popular
deep learning architecture, Convolutional Neural Network (CNN). CNN is an architecture
that contains one or more convolutional layers often followed by a pooling layer. A pooling
layer down-samples the output of the previous layer and provides a way of generalization of
the features that are learned by the filters. On top of the convolutional and pooling layers,
the model is completed with one or more fully connected (FC) layers. The most powerful
feature of CNN models is their ability to capture the local dependencies with the help of
filters. Therefore, the number and size of the filters in a CNN directly affects the type of
features the model learns from the input. It is often reported that as the number of filters
increases, the model becomes better at recognizing patterns [33].
7Figure 2. DeepDTA model with two CNN blocks to learn from compound SMILES and
protein sequences.
We proposed a CNN-based prediction model that comprises two separate CNN blocks,
each of which aims to learn representations from SMILES strings and protein sequences.
For each CNN block, we used three consecutive 1D-convolutional layers with increasing
number of filters. The second layer had double and the third convolutional layer had triple
the number of filters in the first one. The convolutional layers were then followed by the
max-pooling layer. The final features of the max-pooling layers were concatenated and fed
into three FC layers, which we named as DeepDTA. We used 1024 nodes in the first two FC
layers, each followed by a dropout layer of rate 0.1. Dropout is a regularization technique
that is used to avoid over-fitting by setting the activation of some of the neurons to 0 [53].
The third layer consisted of 512 nodes and was followed by the output layer. The proposed
model that combines two CNN blocks is illustrated in Figure 2.
As the activation function, we used Rectified Linear Unit (ReLU) [42], g(x) = max(0, x),
which has been widely used in deep learning studies [36]. A learning model tries to minimize
the difference between the expected (real) value and the prediction during training. Since
we work on a regression task, we used mean squared error (MSE) as the loss function, in
which P is the prediction vector, and Y corresponds to the vector of actual outputs. n
indicates the number of samples.
MSE =
1
n
n∑
i=1
(Pi − Yi)
2 (2)
8The learning was completed with 100 epochs and mini-batch size of 256 was used to update
the weights of the network. Adam was used as the optimization algorithm to train the
networks [35] with the default learning rate of 0.001. We used Keras’ Embedding layer
to represent characters with 128-dimensional dense vectors. The input for Davis data set
consisted of (85,128) and (1200, 128) dimensional matrices for the compounds and proteins,
respectively. We represented KIBA data set with a (100,128) dimensional matrix for the
compounds and a (1000, 128) dimensional matrix for the proteins.
Experiments and Results
Here, we propose a novel drug - target binding affinity prediction method based on only
sequence information of compounds and proteins. We utilized the Concordance Index (CI)
to measure the performance of the proposed model and compared it with the current state-of-
art methods that we chose as our baselines, namely a Kronecker Regularized Least Squares
(KronRLS) based approach [47] and SimBoost [29]. We provide more information about
these baseline methodologies, our model and experimental setup, as well as our results in
the following subsections.
Baselines
Kron-RLS
KronRLS aims to minimize the following function, where f is the prediction function [47]:
J(f) =
m∑
i=1
(yi − f(xi))
2 + λ||f ||2k (3)
||f ||2k is the norm of f , which is related to the kernel function k, and λ > 0 is a regular-
ization hyper-parameter defined by the user. A minimizer for Equation 3 can be defined as
follows [34]:
f(x) =
m∑
i=1
aik(x, xi) (4)
where k is the kernel function. In order to represent compounds, they utilized a similarity
matrix computed using Pubchem structure clustering server (Pubchem Sim)(http://pubchem.ncbi.nlm.nih.gov),
a tool that utilizes single linkage for cluster and uses 2D properties of the compounds to mea-
sure their similarity. As for proteins, the Smith-Waterman algorithm was used to construct
a protein similarity matrix [52].
SimBoost
SimBoost is a gradient boosting machine based method that depends on the features con-
structed from drugs, targets and drug-target pairs [29]. The proposed methodology uses
feature engineering to build three types of features: (i) object-based features that utilize
occurrence statistics and pairwise similarity information of drugs and targets, (ii) network-
based features such as neighbor statistics, network metrics (betweenness, closeness etc.),
PageRank score, which are collected from the respective drug-drug and target-target net-
works (In a drug-drug network, drugs are represented as nodes and connected to each other
9if the similarity of these two drugs is above a user-defined threshold. The target-target
network is constructed in a similar way.) (iii) network-based features that are collected
from a heterogeneous network (drug-target network) where a node can either be a drug or
target and the drug nodes and target nodes are connected to each other via binding affinity
value. In addition to the network metrics, neighbor statistics and PageRank scores, as well
as latent vectors from matrix factorization are also included in this type of network.
These features are fed into a supervised learning method named gradient boosting re-
gression trees [10, 11] derived from gradient boosting machine model [21]. With gradient
boosting regression trees, for a given drug-target pair dti, the binding affinity score y¯ pre-
dicted as follows [29]:
y¯i = θ(dti) =
M∑
m=1
fm(dti), fm ∈ F (5)
in whichM denotes the number of regression trees and F represents the space of all possible
trees. A regularized objective function to learn the set of trees fm is described in the
following form [29]:
R(θ) =
∑
i
l(yi, y¯i) +
∑
m
α(fm) (6)
where l is the loss function that measures the difference between the actual binding affinity
value yi and the predicted value y¯i, while α is the tuning parameter that controls the
complexity of the model. The details are described in [10, 11, 29]. Similar to [47], [29]
also used PubChem clustering server for drug similarity and Smith-Waterman for protein
similarity computation.
Evaluation Metrics
To evaluate the performance of a model that outputs continuous values, Concordance Index
(CI) was used [26]:
CI =
1
Z
∑
δi>δj
h(bi − bj) (7)
where bi is the prediction value for the larger affinity δi, bj is the prediction value for the
smaller affinity δj , Z is a normalization constant, h(m) is the step function [47]:
h(x) =


1, if x > 0
0.5, if x = 0
0, if x < 0
(8)
The metric measures whether the predicted binding affinity values of two random drug-
target pairs were predicted in the same order as their true values were. We used paired-t
test for the statistical significance tests with 95% confidence interval. We also used MSE,
which was explained in Section , as an evaluation metric.
Experiment Setup
We evaluated the performance of the proposed model on the benchmark data sets [17, 54]
similarly to [29]. They used nested-cross validation to decide on the best parameters for
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each test set. In order to learn a generalized model, we randomly divided our data set into
six equal parts in which one part is selected as the independent test set. The remaining parts
of the data set were used to determine the hyper-parameters via five-fold cross validation.
Figure 3 illustrates the partitioning of the data set. The same setting with the same train
and test folds was used for KronRLS [47] and Simboost [29] for a fair comparison.
Figure 3. Experiment setup.
We decided on three hyper-parameters for our model, namely the number of the filters
(same for proteins and compounds), the length of the filter size for compounds, and the
length of the filter size for proteins. We opted to experiment with different filter lengths
for compounds and proteins instead of a common length, due to the fact that they have
different alphabets. The hyper-parameter combination that provided the best average CI
score over the validation set was selected as the best combination in order to model the test
set. We first experimented with hyper-parameters chosen from a wide range and then fine-
tuned the model. For example, to determine the number of filters we performed a search
over [16, 32, 64, 128, 512]. We then narrowed the search range around the best performing
parameter (e.g. if 16 was chosen as the best parameter, then our range was updated as [4,
8, 16, 20] etc.).
As explained in the Proposed Model subsection, the second convolution layer was set to
contain twice the number of filters of the first layer, and the third one was set to contain
three times the number of filters of the first layer. 32 filters gave the best results over the
cross-validation experiments. Therefore, in the final model, each CNN block consisted of
three 1D convolutions of 32, 64, 96 filters. For all test results reported in Table 3 we used
the same structure summarized in Table 2 except for the lengths of the pre-fine-tuned filters
that were used for the compound CNN-block and protein CNN-block.
Table 2. Parameter settings for CNN based DeepDTA model
Parameters Range
Number of filters 32*1; 32*2; 32*3
Filter length (compounds) [4,6,8]
Filter length (proteins) [4,8,12]
epoch 100
hidden neurons 1024; 1024; 512
batch size 256
dropout 0.1
optimizer Adam
learning rate (lr) 0.001
In order to provide a more robust performance measure, we evaluated the performance
over the independent test set, when the model was trained with the learned parameters in
Table 2 on the five training sets that we used in five-fold cross validation (note that the
validation sets were not used). The final CI score was reported as the average of these five
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results. Keras [13] with Tensorflow [1] back-end was used as development framework. Our
experiments were run on OpenSuse 13.2 (3.50GHz Intel(R) Xeon(R) and GeForce GTX
1070 (8GB)). The work was accelerated by running on GPU with cuDNN [12]. We provide
the train and test folds of the data sets (https://github.com/hkmztrk/DeepDTA/).
Results
In this study, we propose a deep-learning model that uses two CNN-blocks to learn repre-
sentations for drugs and targets based on their sequences. As a baseline for comparison, the
KronRLS algorithm and SimBoost methods that use similarity matrices for proteins and
compounds as input were used. The Smith-Waterman (S-W) and Pubchem Sim algorithms
were used to compute the pairwise similarities for the proteins and ligands, respectively.
We then used these S-W and Pubchem Sim similarity scores as inputs to the FC part of
our model (DeepDTA) to evaluate the model. Finally, we used three alternative combina-
tions in learning the hidden patterns of the data and used this information as input to our
DeepDTA model. The combinations were (i) learning only compound representation with
a CNN block and using S-W similarity as protein representation , (ii) learning only protein
sequence representation with a CNN block and using Pubchem Sim to describe compounds,
and (iii) learning both protein representation and compound representations with a CNN
block. We call the last combination used with DeepDTA the combined model.
Tables 3 and 4 report the average MSE and CI scores over the independent test set of
the five models trained with the same parameters (shown in Table 2) using the five different
training sets for Davis and KIBA data sets.
Table 3. The average CI and MSE scores of the test set trained on five different training
sets for the Davis data set. The standard deviations are given in parenthesis.
Proteins Compounds CI (std) MSE
KronRLS [47] Smith-Waterman Pubchem Sim 0.871 (0.0008) 0.379
SimBoost [29] Smith-Waterman Pubchem Sim 0.872 (0.002) 0.282
DeepDTA Smith-Waterman Pubchem Sim 0.790 (0.009) 0.608
DeepDTA CNN Pubchem Sim 0.835 (0.005) 0.419
DeepDTA Smith-Waterman CNN 0.886 (0.008) 0.420
DeepDTA CNN CNN 0.878 (0.004) 0.261
Table 4. The average CI and MSE scores of the test set trained on five different training
sets for the KIBA data set. The standard deviations are given in parenthesis.
Proteins Compounds CI (std) MSE
KronRLS [47] Smith-Waterman Pubchem Sim 0.782 (0.0009) 0.411
SimBoost [29] Smith-Waterman Pubchem Sim 0.836 (0.001) 0.222
DeepDTA Smith-Waterman Pubchem Sim 0.710 (0.002) 0.502
DeepDTA CNN Pubchem Sim 0.718 (0.004) 0.571
DeepDTA Smith-Waterman CNN 0.854 (0.001) 0.204
DeepDTA CNN CNN 0.863 (0.002) 0.194
In the Davis data set, SimBoost and KronRLS methods perform similarly while the CI
values for SimBoost is higher than that for KronRLS in the larger KIBA dataset. When
the similarity measures S-W, for proteins, and Pubchem Sim, for compounds, are used with
the the fully-connected part of the neural networks (DeepDTA), the CI drops to 0.79 for
the Davis data set and to 0.71 for the KIBA data set. The MSE increases to more than
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0.5. These results suggest that the use of a feed-forward neural network with predefined
features is not sufficient to describe drug target interactions and to predict drug target
affinities. Therefore, we used CNN layers to learn representations of drugs and proteins to
capture hidden patterns in the datasets.
We first used CNN to learn representations of proteins and used the predefined Pubchem
Sim scores for the ligands. Using this combination did not improve the results suggesting
that use of a CNN architecture is not effective enough to learn from amino acid sequences.
Then we used the CNN block to learn compound representations from SMILES and used
the predefined S-W scores for the proteins. This combination outperformed the baselines
on the KIBA data set with statistical significance (p-value of 0.0001 for both SimBoost
and KronRLS), and on the Davis data set (p-value of around 0.03 for both SimBoost and
KronRLS). These results suggested that the CNN is able to capture more information than
Pubchem Sim in the compound representation task.
Motivated by this result, we tested the combined CNN model in which both protein
and compound representations are learned from the CNN layer. This method performed as
well as the baseline methods with CI score of 0.878 on the Davis data set and achieved the
best CI score (0.863) on the KIBA data set with statistical significance over both baselines
(p-value of 0.0001 for both). The MSE values of this model were also notably lower than the
MSE of the baseline models on both data sets. Even though learning protein representations
with CNN was not effective, combination of the two CNN blocks for proteins and ligands
provided a strong model.
Conclusion
We propose a deep-learning based approach to predict drug-target binding affinity using only
sequences of proteins and drugs. We use Convolutional Neural Networks (CNN) to learn
representations from the raw sequence data of proteins and drugs and fully connected layers
(DeepDTA) in the affinity prediction task. We compare the performance of the proposed
model with two recent studies that employed the KronRLS regression algorithm [47] and the
SimBoost method [29] as our baselines. We perform our experiments on the Davis kinase -
drug data set and the KIBA data set.
Our results showed that the use of predefined features with DeepDTA is not sufficient
to describe protein - ligand interactions. However, when two CNN-blocks that learn repre-
sentations of proteins and drugs based on raw sequence data are used in conjunction with
DeepDTA, the performance increases significantly compared to both baseline methodologies
for both KIBA and Davis data sets. Furthermore, the model that uses CNN to learn com-
pound representations from SMILES and S-W similarities of proteins also achieves better
performance than the baselines.
We observed that the model that uses CNN-block to learn proteins and 2D compound
similarity to represent compounds performed poorly compared to the other methods that
employ CNN. This might be an indication that amino-acids require a structure that can
handle their ordered relationships, which the CNN architecture failed to capture successfully.
Long-Short Term Memory (LSTM), which is a special type of Recurrent Neural Networks
(RNN), could be a more suitable approach to learn from protein sequences, since the ar-
chitecture has memory blocks that allow effective learning from a long sequence. LSTM
architecture has been successfully employed to tasks such as detecting homology [31], con-
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structive peptide design [41] and function prediction [39] that utilize amino-acid sequences.
As future work, we also aim to utilize a recent ligand-based protein representation method
proposed by our team that uses SMILES sequences of the interacting ligands to describe
proteins [46] .
The results indicated that deep-learning based methodologies performed notably better
than the baseline methods with a statistical significance when the data set grows in size, as
the KIBA data set is four times larger than the Davis data set. The improvement over the
baseline was significantly higher for the KIBA data set (from CI score of 0.836 to 0.863)
compared to the Davis data set (from CI score of 0.872 to 0.878). The increase in the data
enables the deep learning architectures to capture the hidden information better.
The major contribution of this study is the presentation of a novel deep learning-based
model for drug - target affinity prediction that uses only character representations of pro-
teins and drugs. By simply using raw sequence information for both drugs and targets, we
were able to achieve similar or better performance than the baseline methods that depend
on multiple different tools and algorithms to extract features.
A large percentage of proteins remains untargeted, either due to bias in the drug discovery
field for a select group of proteins or due to their undruggability, and this untapped pool
of proteins has gained interest with protein deorphanizing efforts [19, 20, 43]. As future
work, we will focus on building an effective representation for protein sequences. The
methodology can then be extended to predict the affinity of known compounds/targets to
novel targets/drugs as well as to the prediction of the affinity of novel drug-target pairs.
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